Cell-free methylated DNA immunoprecipitation and high throughput sequencing technology: diagnostic value in patients with renal cell carcinoma. by Nuzzo, PIER VITALE
1 
 
 UNIVERSITY OF GENOA, ITALY 




XXXI cycle Ph.D. course: 
















Francesco Boccardo, MD 
Full Professor of Medicine 
University of Genova, Italy 




Pier Vitale Nuzzo, MD 
Supervisors: 
 
Matthew L. Freedman, M.D. 
Associate Professor of Medicine 
Harvard Medical School 
Dana-Farber Cancer Institute, Boston,MA, USA 
 
Toni K. Choueiri, MD 
Full Professor of Medicine 
Harvard Medical School 
Dana-Farber Cancer Institute, Boston,MA, USA 
 
CELL-FREE METHYLATED DNA 
IMMUNOPRECIPITATION AND HIGH THROUGHPUT 
SEQUENCING TECHNOLOGY: DIAGNOSTIC VALUE 






I hereby declare that this dissertation is my own original work and that I have fully acknowledged 
by name all of those individuals and organizations that have contributed to the research for this 
dissertation. Due acknowledgement has been made in the text to all other material used. 
Throughout this dissertation and in all related publications I followed the guidelines of “Good 
Scientific Practice”. 
 
Individuals and organizations that have contributed to the research for this dissertation: 
 
• Academic Unit of Medical Oncology, IRCCS San Martino University Hospital - IST 
National Cancer Research Institute, University of Genoa, Genoa, Italy. 
• Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. 
• Dana Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Harvard Medical 
School, Boston, MA 
• Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 
Boston, MA, USA;  
• The Eli and Edythe L. Broad Institute, Cambridge, MA 02142, USA. 










Table of Contents 
Acknowledgments ........................................................................................................................... 5 
1. Introduction ................................................................................................................................. 6 
2. Renal Cell Carcinoma................................................................................................................. 7 
2.1 Epidemiology ......................................................................................................................... 7 
2.2 Risk factors ............................................................................................................................. 7 
2.3 Pathology  ............................................................................................................................... 9 
2.4 Clinical manifestation ........................................................................................................... 10 
2.5 Diagnostic evaluation ........................................................................................................... 10 
2.6 Tissue diagnosis ................................................................................................................... 11 
2.7 Staging imaging studies  ....................................................................................................... 11 
2.8 TNM Staging System ........................................................................................................... 11 
3. Circulating cell-free DNA......................................................................................................... 12 
3.1 Origin and characteristics of cfDNA  ................................................................................... 12 
3.2 Technical aspects  ................................................................................................................. 13 
3.2.1 Blood sampling and processing ................................................................................. 13 
3.2.2 Detection of cfDNA ................................................................................................... 15 
4. Circulating cell-free DNA and Renal Cell Carcinoma .......................................................... 16 
4.1 CfDNA levels ....................................................................................................................... 16 
4.2 CfDNA integrity ................................................................................................................... 17 
4.3 CfDNA genetic and epigenetic abnormalities ...................................................................... 18 
5. Circulating cell-free methylated DNA and Renal Cell Carcinoma ...................................... 20 
5.1 DNA methylation and cancer ............................................................................................... 20 
5.2 CfmeDNA as a potential biomarker in cancer  .................................................................... 21 
5.3 Cell-free methylated DNA immunoprecipitation and high-throughput sequencing 
methodology ............................................................................................................................... 22 
5.4 Preliminary results ................................................................................................................ 23 
6. Rationale and aims .................................................................................................................... 24 
6.1 Rationale and Hypothesis  .................................................................................................... 24 
6.2 Aim of the study ................................................................................................................... 24 
7. Material and methods ............................................................................................................... 25 
7.1 Patient selection .................................................................................................................... 25 
4 
 
7.2 Ethical remarks ..................................................................................................................... 25 
7.3 Sample acquisition ............................................................................................................... 25 
7.4 Specimen processing for patient cfDNA .............................................................................. 25 
7.5 cfMeDIP–seq protocol ......................................................................................................... 25 
7.6 Concentration of cfDNA, calculation and visualization of differentially methylated regions 
from cfDNA of patients with renal cell carcinoma and healthy donors ..................................... 27 
7.7 Data reporting ....................................................................................................................... 27 
7.8 Bioinformatic simulation of tumour-specific features and probability of detection by 
sequencing depth ........................................................................................................................ 28 
8. Results  ....................................................................................................................................... 28 
9. Discussion................................................................................................................................... 29 
10. Conclusion ............................................................................................................................... 32 
11. Tables and figures ................................................................................................................... 33 

























I would like to thank Prof. Matthew Freedman for giving me the opportunity to be a part of his 
research team and for letting me conduct my PhD under his supervision. Thank you for all of your 
scientific advice, discussions, corrections and for giving me the opportunity to experience different 
research cancer areas at high level. 
 
I would like to express my sincere gratitude to Prof. Toni Choueiri, for providing me this 
opportunity, for his patient guidance, enthusiastic encouragement and useful critiques of this 
research work. Thanks for letting me be a part of your clinical research family and the precious 
networking. 
 
I also 1acknowledge De Carvalho Daniel’s laboratory from the Princess Margaret Cancer Centre, 
Toronto, ON for their scientific and precious collaboration in this research study. My sincere thanks 
also go to Ankur Shen Roxana for all the computational assistance and bioinformatics analysis.  
 
I would also like to express my deep thanks to all members and lovely friends of Freedman’s 
laboratory. I am proud to work with a team full of ambitious people who continue to deliver 
excellent results. Thanks for the support and friendship. You're the most amazing coworkers. 
 
In particular, would like to express my sincere gratitude to Sandor Spisak for the continuous support 
of my PhD study, for his patience, motivation, and immense knowledge. Your guidance helped me 
to increase my scientific abilities in the research area. Thanks for sharing your scientific knowledge 
and tricks with me and for teaching me a lot of scientific technologies and procedures. 
 
I gratefully acknowledge the patients for participating in this study and my loving family for their 
support and encouragement through my entire life. 
 
Last but least, I express my gratitude to Prof. Francesco Boccardo and Prof.ssa Alessandra 
Rubagotti for all the things they taught me during my residency and for the opportunity to be in 
Boston. I am grateful to Prof. Boccardo, who raised me with a love of science and supported me in 
all my pursuits and has been my guide of science, endurance and patience. I’m grateful for all of 













Renal cell carcinoma (RCC) is the third most common urological cancer of men and represents 
approximately 3% of all malignant disease1. In 2012, 338,000 new cases were newly diagnosed 
and cancer-related deaths were 143,000 worldwide2.  
Nowadays RCC diagnosis is commonly incidental, based on radiologic procedures performed for 
other indications3,4. At diagnosis, nearly 70% of patients presents with localized disease, whereas 
15% has regional disease and 15% distant metastases5. For those with localized RCC and selected 
patients with advanced RCC, radical or partial nephrectomy (RN) can be curative6,7. However, 
around one third of patients who underwent resection of localized disease eventually recurs 
distant8. Known prognostic classifications based on clinic-pathological features, such as TNM 
stage and Fuhrman grade, showed limited ability to estimate risk of recurrence for these 
patients9,10. 
Therefore, there is an urgent need to identify simple and reliable markers to enhance diagnostic 
accuracy and better determine the risk of relapse following nephrectomy. 
In the past few years, as the concordance of genetic alterations between cell-free DNA (cfDNA) 
and matched tumor biopsies was validated11, there has been increasing enthusiasm over the use of 
cfDNA as a potential blood cancer biomarker. In fact, cfDNA could serve as a “liquid biopsy” 
enabling comprehensive tumor genomic profiling from blood at various time points, without the 
shortcomings of invasive tissue biopsies11,12. 
Obstacles to analyzing traditional circulating tumor DNA (ctDNA) relate to sensitivity given the 
limited number of recurrent mutations available in order to properly distinguish between tumor 
and normal circulating cfDNA in a cost-effective manner and the technical artefacts as a result of 
sequencing. On the other hand, the use of cell-free methylated DNA (cfmeDNA) fragments from 
cfDNA would overcome these issues.  
The advantages of developing cfmeDNA as a biomarker are three-fold: 1) methylation status 
differs between normal and malignant tissues13; 2) methylation status is tissue-specific, which 
permits inference on tissue origin14,15; and 3) the ‘target size’ for methylation is larger than 
individually identifying a handful of somatically acquired genetic alterations, thereby improving 
dramatically its sensitivity and dynamic range.  
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The group of Daniel De Carvalho (Princess Margaret Cancer Centre, University Health Network, 
Toronto, ON), developed a novel, optimized technology, namely the cfMeDIP-seq (cell-free 
methylated DNA immunoprecipitation and high-throughput sequencing) for genome-wide 
bisulfite-free plasma DNA methylation profiling. This methodology permits an enrichment for 
CpG rich, thereby overcoming the fragmented nature of plasma cfDNA, and thus enhancing cost-
effectiveness16. Their first approach was the optimization of the gold standard low-input MeDIP-
seq protocol, reducing the 100 ng input of DNA to only 1-10ng input DNA17 
In this thesis, we will evaluate the sensitivity and specificity of cfMeDIP-seq technology to early 
detect RCC in a plasma samples of RCC patients at stage I, II and III, collected before RN. 
 
2. RENAL CELL CARCINOMA 
2.1 Epidemiology 
Globally, the incidence of RCC varies widely from region to region, with the highest rates 
observed in the Czech Republic and North America18. In the United States, there are 
approximately 65,000 new cases and almost 15,000 deaths from RCC each year1. In the European 
Union, there were approximately 84,000 cases of RCC and 35,000 deaths due to kidney cancer in 
201219. 
RCC is approximately 50 percent more common in men compared with women occurs 
predominantly in the sixth to eighth decade of life with median age at diagnosis around 64 years 
of age1,20. 
Within the United States, Asian Americans or Pacific Islanders have the lowest incidence of renal 
cancers compared with American Indians/Alaska natives, Hispanic/Latinos, Whites, or African 
Americans1. 
Nowadays RCC diagnosis is commonly incidental, based on radiologic procedures performed for 
other indications 3,4. At diagnosis, nearly 70% of patients presents with localized disease, whereas 
15% has regional disease and 15% distant metastases5. For those with localized RCC and selected 
patients with advanced RCC, RN can be curative6,7. However, around one third of patients who 
underwent resection of localized disease eventually recurs distantly8. 
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The five-year survival rate of patients with kidney cancer has doubled over the last 50 years, from 
34 percent in 1954 to 62 percent in 1996, and to 73 percent from 2005 to 201121. The incidence 
of RCC has risen threefold higher than the mortality rate, mostly due to earlier detection of these 
tumors at smaller sizes and curative surgical treatment22. 
 
2.2 Risk factors 
Smoking is a well-established risk factor for RCC. The relative risks for RCC for all smokers, 
current smokers, and former smokers were 1.31, 1.36, and 1.16, respectively23. Another known 
risk is the hypertension, which seems to be independent of anti-hypertensive medications or 
obesity24.  
Obesity is another risk factor for RCC in both men and women25. The relative risk (RR) of RCC 
increased progressively with baseline body mass index (BMI). For patients with newly diagnosed 
RCC, excess body weight is associated with a lower stage and lower grade disease26. Furthermore, 
in patients with metastatic disease, RCC is associated with a longer overall survival for those with 
excess body weight compared with those with normal or below normal body weight27. Acquired 
cystic disease of the kidney is a definitive risk factor for RCC. It develops in approximately 35 to 
50 percent of chronic dialysis patients, approximately 6 percent who eventually develop RCC28.  
Occupational exposure to toxic compounds, such as cadmium, asbestos, and petroleum by-
products, has been associated with an increased risk of RCC, although studies of occupational 
exposures are often limited by the lack of specific exposure details29.  
The other risk factor that have been linked to RCC is the use of analgesics. Epidemiologic studies 
have demonstrated an increased risk for RCC with heavy use of aspirin, non-steroidal anti-
inflammatory drugs (NSAIDS), and acetaminophen, although the risk may vary depending upon 
the agent30.  
Approximately 2-3% of cases are familial and several hereditary RCC syndromes have been 
described including von Hippel-Lindau syndrome, hereditary papillary RCC, hereditary 
leiomyomatosis RCC, Birt-Hogg-Dubé, and tuberous sclerosis31,32. Among these, the von Hippel-
Lindau syndrome is most notable.  
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Additional clinical factors may increase the risk of developing RCC, such as diabetes mellitus33, 
polycystic kidney disease34, and dietary factors such as the intake of nitrite from processed meat 
sources35, reproductive factors (eg, increasing number of pregnancies), and prior radiation therapy 
(RT)36. Conversely, alcohol intake is associated with a protective effect on the risk of RCC in both 
men and women37 and the use of oral contraceptives in women may reduce risk38. 
 
2.3 Pathology  
Histopathological examination of tumor tissue is necessary to confirm the diagnosis of RCC. 
Then, RCC is classified histologically into different subtypes.  
The classification reflects the morphology, growth pattern, cell of origin, histochemical, and 
molecular basis of the different types of adenocarcinomas39,40.  
Clear cell carcinoma is the most common subtype and accounts for 75% of the cases41. Clear cell 
refers to the high lipid content in cytoplasm that is dissolved during histological preparation, 
resulting in a lucent or clear cytoplasm. In the remaining cases, papillary carcinoma, chromophobe 
carcinoma and collecting duct carcinoma are described, which represent 10-15%, 5-10% and 1% 
of the cases, respectively39,40. 
Because clear cell carcinoma is the most common subtype of RCC, much work has been done to 
classify these cancers based on genetic alterations. 
The common genetic abnormalities in RCC was found in von-Hippel Lindau (VHL) gene42. The 
VHL gene is found on chromosome 3 (3p25 to 26) and plays a pivotal role in the development of 
clear cell RCC in patients with VHL disease. In addition, VHL gene alterations appear to be 
important in the pathogenesis of sporadic RCC43,44. In one report of 187 patients with sporadic 
RCC, somatic mutations or promoter hypermethylation in the VHL gene was observed in 58 
percent of cases42. Other reports using high throughput methodologies have demonstrated 
improved identification of VHL alterations; up to 91 percent of patients with clear cell RCC harbor 





2.4 Clinical manifestation 
Patients with RCC can present with a range of symptoms; unfortunately, many patients are 
asymptomatic until the disease is advanced. At presentation, approximately 25 percent of 
individuals either have distant metastases or advanced locoregional disease45. 
Patients with localized disease can present with a wide array of symptoms and/or laboratory 
abnormalities, or they may be diagnosed incidentally. In the past, the most common presenting 
symptoms were hematuria, abdominal mass, pain, and weight loss45. In contemporary series, there 
is an increased frequency of incidental diagnosis due to radiologic procedures performed for other 
indications. This shift in pattern of presentation along with improvements in therapy may have 
contributed to better outcomes in RCC46.  
Patients with RCC can also present with or subsequently develop systemic symptoms or 
paraneoplastic syndromes47. In some instances, these may be due to ectopic production of various 
hormones (eg, erythropoietin, parathyroid hormone-related protein [PTHrP], gonadotropins, 
human chorionic somatomammotropin, an adrenocorticotropic hormone [ACTH]-like substance, 
renin, glucagon, insulin)47. 
 
2.5 Diagnostic evaluation 
The usual first diagnostic test is abdominal computed tomography (CT) or, occasionally, 
abdominal ultrasound48. Although ultrasonography is less sensitive than CT in detecting a renal 
mass, it is useful to distinguish a simple benign cyst from a more complex cyst or a solid tumor.  
If the ultrasonography is not sufficient, the patient should undergo CT before and after injection 
of iodinated contrast. On CT, a simple cyst has a smooth appearance without a clearly delineated 
wall, has no enhancement with intravascular contrast, and is the density of water. CT urography 
allows imaging of both the renal parenchyma and the collecting system49. 
Magnetic resonance imaging (MRI) may be useful when ultrasonography and/or CT are 
inconclusive or if iodinated contrast cannot be administered because of allergy or poor renal 
function. MRI is particularly helpful in cases where a neoplasm is diagnosed as it evaluates for 




2.6 Tissue diagnosis 
RN is used in most cases to obtain tissue for diagnosis of RCC prior to treatment, although the 
diagnosis of RCC is occasionally established by a biopsy of a metastasis. After the presumptive 
diagnosis has been made based upon imaging studies, the patient must be evaluated for the extent 
of local involvement and the presence of metastatic disease prior to surgery. 
The role of percutaneous biopsy is more limited, although it may be used for a small renal mass 
if there is a high index of suspicion for a metastatic lesion to the kidney, lymphoma, or a focal 
kidney infection51. A biopsy can also be used to confirm a diagnosis of RCC in patients who are 
not surgical candidates prior to initiating appropriate medical treatment, although biopsy of a 
metastatic lesion is often preferable52. 
 
2.7 Staging imaging studies  
The extent of local and regional involvement is determined primarily by abdominal CT, which is 
extremely accurate in staging RCC.  Other procedures that may be useful for assessing for distant 
metastases include bone scan, CT of the chest, MRI, and PET/CT. 
Bone scan is indicated only in patients with bone pain and/or an elevated serum alkaline 
phosphatase53. CT of the chest is useful to evaluate for evidence of pulmonary or mediastinal 
lymph node metastases54. MRI scanning with gadolinium is superior to CT for evaluation of the 
inferior vena cava and right atrium when tumor involvement is suspected55. PET scanning has 
high sensitivity and specificity for the primary lesion. Although PET or PET/CT may be more 
sensitive than radionuclide scanning for the detection of bone metastases, it is expensive and has 
limited use for routine staging56. 
 
2.8 TNM Staging System 
The eighth (2017) Tumor, Node, Metastasis (TNM) staging system is used for staging all 
histologic variants of RCC. This system is supported by both the American Joint Committee on 
Cancer (AJCC) and the International Union for Cancer Control (UICC)49. These TNM criteria use 
the anatomic extent of disease to define prognostic stage groups.  
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The TNM system is shown in the table (table 1). In this system, tumors limited to the kidney are 
classified as T1 or T2 based upon size. T3 tumors extend into the renal vein or perinephric tissues 
but not beyond the Gerota fascia, while T4 tumors extend beyond the Gerota fascia, including 
direct extension into the ipsilateral adrenal gland. Nodal and distant metastases are simply 
classified as absent or present. 
 
3. CIRCULATING CELL-FREE DNA 
3.1 Origin and characteristics of cfDNA  
cfDNA are single- or double-stranded extracellular fragments of deoxyribonucleic acids with a 
molecular weight ranging from 0.16 kb to 21kb that circulate in plasma, serum, and other bodily 
fluids outside of cells11.  
The presence of cfDNA in human blood was initially reported in 1948 by Mandel and Métais in 
healthy individuals, pregnant women, and sick individuals57. However, this did not arise much 
interest until 1977 when Leon et al. suggested the possibility of exploiting cfDNA as tumor 
biomarker for the first time58. Only 10 years later, Stroun et al. demonstrated the presence of 
neoplastic characteristics in the cfDNA of cancer patients59. Subsequently, several studies 
reported the possible use of cfDNA as a biomarker for cancer patients and a variety of alterations 
in cfDNA including point mutations, deletions, DNA hypermethylation, copy number variation 
(CNV), microsatellite instabilities (MI), and losses of heterozygosity (LOH) have been 
investigated11. 
CfDNA can be present in the bloodstream as “naked” DNA, free from any binding to other 
molecules or surfaces60,61, wrapped around histone proteins in nucleosome structures62, or 
internalized in vesicles63 which protect it from nucleases and prevent its exposure to the immune 
system, or in virtosome structures, bound to particular structures, such as apoptotic bodies, serum 
carrier proteins, or anti-DNA antibodies64. Furthermore, cfDNA can be observed attached to the 
exterior of the cell membrane or adsorbed on the surface of blood cells from which it can be freed 
into the circulatory system65,66. 
The biological mechanisms which underlie cfDNA shedding into the bloodstream remain to be 
fully elucidated. In healthy individuals, cfDNA could result from cell apoptosis or necrosis or 
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living cells actively releasing DNA fragments67,68. The analysis of cfDNA fragmentation revealed 
that most of the cfDNA fragments measure between 160bp and 200bp indicating that the majority 
is produced by apoptosis. However, DNA fragments of higher molecular length, similar to 
necrotic cell DNA, were also detected in several samples11.  
CtDNA is a fragment of DNA that originates from tumor cells and thus harbors cancer-related 
mutations69. This characteristic differentiates it from cfDNA which more broadly defines any 
DNA freely circulating in the bloodstream. ctDNA can vary between 0.01% and more than 90% 
of total cfDNA depending on different clinical cancer histories69,70. CtDNA was detectable at 
lower concentration in patients with localized cancers and at high concentration in the circulation 
of most patients with metastatic cancer, reaching more than 75% in metastatic pancreatic, ovarian, 
colorectal, bladder, breast, melanoma, hepatocellular and head and neck cancers71. However in 
RCC, ctDNA was detectable in less than 50% of patients with metastatic disease and in 20% of 
patients of primary disease71.  
The mechanisms hypothesized underpining the release of ctDNA comprise active secretion of 
tumor cells, including primary tumor, lysis of tumor cells that circulate in the blood or 
micrometastases shed by tumor, passive release from apoptotic and necrotic tumor cells, or other 
physiological events induced by microenvironmental stress and treatment pressure68,72,73.  
Currently, there are no data available on the kinetics of cfDNA in RCC. Some reports in other 
tumors suggested that the clearance of cfDNA occurs rapidly, ranging from 15 minutes to several 
hours70 29. The elimination process is characterized by a rapid phase with a mean half-life of 
approximately 1 hour, of which liver, spleen, and kidney may be responsible, and a slower phase 
with a mean half-life of approximately 13 hours, probably due to the activity of plasma 
nucleases60,69,74.  
Although cancer patients have higher levels of cfDNA compared to healthy individuals, the 
cfDNA concentrations alone does not seem to be useful to distinguish healthy individual from 
patients with benign and malignant disease. In cancer patients, the concentration of cfDNA in the 
plasma or in the serum varies up to 50 times the normal level71, based on tumor burden, stage, 
cellular turnover, response to therapy, and the presence of DNAse inhibitors71. However increase 
of cfDNA is also observed in several other pathologies, such as multiple sclerosis75, stroke76, 
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hemodialysis77, pancreatitis78, trauma76, aging79, and after transplantation80, systemic lupus 
erythematosus (LES)81, and  cardiovascular diseases82,83. 
 
3.2 Technical aspects 
The numerous discrepancies in the results of the studies of cfDNA reported in the literature so far 
are mainly due to the lack of standardization of the various protocols for sample handling and 
processing and to the different techniques used for cfDNA detection and analysis. These issues 
constitute a major bias when comparing data from different studies and are one of the greatest 
obstacles in translating cfDNA to clinical practice. 
 
3.2.1 Blood sampling and processing 
Various blood sampling and processing factors can affect concentrations and integrity of cfDNA 
and they include the type of serum preparation (with or without a coagulation accelerator)84, the 
use of different anticoagulants for plasma collection84,85, the time between collection and 
centrifugation86, the storage temperature of blood before centrifugation86,87, centrifugation 
forces70,88,89 time and temperature-dependent cryopreservation of samples90. A reliable protocol 
should be developed following careful consideration of the above factors based on the literature 
data. 
Despite serum samples having a concentration of cfDNA 3-24 fold higher than plasma, the latter 
is a better source for cfDNA91-94. Much of the cfDNA in the serum is generated in the original 
collection tube during the process of clothing. Therefore, the tube contains a higher proportion of 
cfDNA deriving from white blood cells, which makes detecting ctDNA more difficult91-94.  
Although there is no universal protocol, current knowledge suggests to isolate cfDNA using 5-
10ml of blood which is collected in tubes handled with EDTA or cfDNA collection tubes which 
prevent blood cell lysis85,95. Blood must be processed within 4 hours following the blood draw to 
avoid significant increase in plasma concentration and DNA integrity90. Moreover, centrifugation 
ensures the absence of cells in the plasma and, in this regard, a second high-speed cycle is highly 
recommended. The number of freeze-thaw cycles does not affect the DNA yield, but it leads to 
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fragmentation of DNA90,96. Therefore, plasma must be aliquoted and stored at −80°C or −20°C 
for up to three months for cfDNA concentration and fragmentation analysis or nine months for 
specific sequence detection. In fact, prolonged storage of whole plasma or serum DNA leads to 
substantial DNA degradation, with an annual degradation rate of approximately 30%90,96,97. 
 
3.2.2 Detection of cfDNA 
The efficiency and quality of the cfDNA extraction process are influenced by the protocol chosen 
to isolate cfDNA. That is also partly responsible for the high variability of cfDNA data observed 
among studies. The main methods used for extracting cfDNA can be divided in “commercial 
methods”, a ready-to-use extraction kits based on anion-exchange method, silica-membrane 
technology, or magnetic-particle technology, and “non-commercial methods”, such as phenol-
chloroform extraction, guanidine-resin method, alcohol precipitation, and salting-out method. 
Although many of “non-commercial methods” achieve high yields and enable extraction of more 
small-sized fragments, they include use of toxic solvents, take longer time, and, due to the high 
coefficient of variability in results, they are not appropriate for clinical analyses. Those are the 
reasons why most of the studies were performed by “commercial methods”. They have good 
repeatability and reproducibility and thus enable standardization for clinical studies.  
Once cfDNA was isolated, the two fundamental approaches to analyze cfDNA are based on 
targeted approaches which allow detection of specific known mutations, and untargeted 
approaches that allow identification of events without a priori.  
PCR assays had been a widely used method for quantifying DNA as the concentration of cfDNA 
is within the range of nanograms for accurate measurement. Quantitative PCR (qPCR) measures 
signals from labeled probes during amplification of different target genes (i.e., hTERT, b-globin) 
or total cfDNA, or quantification of tumor specific mutations. It is a very sensitive and 
reproducible method with high sensitivity98,99. The disadvantage of qPCR is the high risk of false 
positivity and the limitation of the single assay, for which a high number of separate assays are 
needed to cover the increasing number of relevant mutations98,99. 
Although PCR can be considered the current standard for detection of multiple mutations 
(multiplexing) from the same sample, with 0.01%-0.1% sensitivity and high specificity, it has 
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limitations in terms of small input of DNA applicable for individual assays100. Instead the 
BEAMing (beads, emulsion, amplification, and magnetic), which detects DNA segments by 
means of amplification using primers with known tag sequences and covalently bound to magnetic 
beads, nevertheless, has a complex workflow, it is time-consuming, and has a relatively high cost 
per sample, which make its implementation in a clinical study setting less feasible. 
In contrast with these approaches that target hotspot mutations new technologies based on untarget 
approaches have been developed, such as next generation sequencing (NGS). It is based on the 
analysis of millions of short sequences from DNA molecules and the subsequent comparison to a 
reference sequence without knowing a priori the genotype of the tumor101,102. Despite the clear 
advantage of enabling detection of multiple somatic alterations simultaneously with high 
sensitivity and specificity, NGS is an expensive and time consuming technique101,103. A capture 
based NGS method of ctDNA detection termed CAPP (cancer personalized profiling by deep 
sequencing) recently showed a significantly higher sensitivity with a lower cost104. Finally, the 
whole exome sequencing (WES) and whole genome sequencing (WGS) techniques not only allow 
screening of mutations but also of rearrangements and of CNV, providing a comprehensive 
genomic profiling of ctDNA105. However, they are still very expensive to be routinely applied for 
clinical diagnosis.  
Due to its high fragmentation, contamination by non tumoral cfDNA, low amount, and fast 
clearance, detection of ctDNA remains challenging and requires ultrasensitive analytical assays. 
 
4. CIRCULATING CELL-FREE DNA AND RENAL CELL CARCINOMA 
The use of cfDNA could help determining early signs of disease and distinguishing benign from 
malignant renal lesions, based on its concentration, integrity and genetic and epigenetic 
abnormalities (table 2). 
 
4.1 CfDNA levels 
In this regard, three studies with more than 300 RCC patients and 141 control subjects overall 
examined cfDNA levels in patients with RCC106-108. Although the interpretation of these studies 
as a whole is hampered by the technical differences between them (serum versus plasma, different 
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cfDNA isolation methods, specific DNA elements used to quantify cfDNA, etc.) as well as the 
diverse disease stages for cancer patients, they showed that cfDNA levels were higher in patients 
with RCC compared with healthy controls.  
In the older of these study the preoperative plasma cfDNA content of RCC patients was eight 
times higher than that of healthy controls (26.4±48.3ng/ml versus controls 3.2±1.5ng/ml)107. The 
statistical significance of this result was maintained even when sex, age, histology, tumor size, 
grading, and pathologic TNM stratifications were applied. Nevertheless, the area under the curve 
(AUC) obtained with receiver operating characteristic (ROC) analysis demonstrated a moderate 
careful discriminating power107. 
Using real-time PCR, Wan et al. also reported increased cfDNA levels in RCC patients compared 
with localized RCC or controls108. However, in this case, there was a significant difference in 
plasma cfDNA levels among RCC patients with different Fuhrman grade, TNM stage, and tumor 
size suggesting an association with the tumor aggressivity108. 
Finally, the largest of the 3 reports analyzed cfDNA levels using hydrolysis probes for the ring 
finger protein 185 gene (RNF185). In patients with RCC, cfDNA levels were significantly higher 
than in patients with benign tumors, indicating that cfDNA may aid in the differential diagnosis 
of solid renal masses106. Furthermore, total cfDNA levels were higher in patients with metastatic 
RCC and necrotic RCC106. Overall, these studies suggest that elevated cfDNA levels in RCC 
patients are associated with high degree necrosis, apoptosis, or success of therapy. However, as 
shown by the ROC analysis of the report by Perego et al, data are not sufficiently robust to 
distinguish between cancer and non-cancer. This is in keep with the fact that cfDNA levels are 
influenced by concomitant diseases and other clinical factors. Therefore, currently cfDNA blood 
concentrations alone cannot be considered a reliable diagnostic tool. 
 
4.2 CfDNA integrity 
Postulating that cfDNA fragments have different lengths in cancer vs. non malignant diseases, 
two studies aimed to analyze the size differences of the cfDNA fragments109,110. Using quantitative 
real-time PCR, Hauser et al. analyzed the serum cfDNA integrity defined as a ratio of the longer 
fragment actine-beta gene 384 (ACTB384) and the shorter fragment actine-beta gene 106 
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(ACTB106)110. The levels of both DNA fragments were increased in the preoperative serum of 
RCC patients (n=35) compared to the healthy individuals (n=54)110. The significantly higher 
presence and increased integrity of the long fragment in cancer patients compared to the healthy 
subjects supported the thesis of necrotic origins and indicated that cfDNA is fragmented to a 
higher degree in cancer patients110. Similarly to Hauser’s analysis, also Gang et al. found higher 
concentration of long fragments of a housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase in the preoperative serum of RCC patients (n=78) compared to those in the healthy 
control group (n=42), suggesting that necrosis is a more frequent event in patients with tumor109. 
Besides, cfDNA integrity was correlated also with tumor stage and size in this cohort109. Although 
the results of the two studies supported the idea that ctDNA is more likely released by necrotic 
cells and thus it is composed of larger fragments compared to non-tumor-derived cfDNA, likely 
released by apoptotic cells, the limited number of samples analyzed, the lack of standardization 
in measuring long and short fragments of cfDNA and the modest sensitivity, specificity and AUC 
values for short and long fragment detection are not enough to suggest that cfDNA size should be 
considered as a reliable diagnostic biomarker. 
 
4.3 CfDNA genetic and epigenetic abnormalities 
As opposed to cfDNA levels and sizes, the detection of genetic (i.e. MI) and epigenetic (i.e., CpG 
island hypermethylation) alterations within ctDNA may be useful to increase the rate of early and 
accurate diagnoses. Eight studies searched for cancer-associated ctDNA alterations common 
across all RCC106,107,111-116 (table 3 and 4). 
Goessl et al., applying only 4 markers for MI in chromosome 3p, was the first to detect plasma 
ctDNA genetic alterations in RCC patients116. While 63% of patients (n=40) had LOH in at least 
one locus and 35% in more than one locus, microsatellite instability was found only in one patient, 
indicating that DNA mismatch repair genes are unlikely to play a major role in renal 
carcinogenesis116. However, those alterations were not associated with tumor stage and only a 
portion was found in the corresponding primary tumor116. Surprisingly, plasma cfDNA alterations 
were not found in the healthy controls (n=10)116. A following report confirmed similar frequency 
of microsatellite alterations in RCC patients serum111. In this case, 60% of patients with malignant 
renal tumor (n=25) had at least one alteration in the 28 microsatellite markers from 20 
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chromosome regions studied111. Interestingly, also in this study none of the controls (n=16) 
showed serum cfDNA and no association between cfDNA alteration and tumor stage was 
found111. Conversely, a later study found microsatellite alterations in 74% of RCC patients using 
9 markers from 3 chromosomal regions and in 87% of RCC using 20 markers for MI112. Most of 
these alterations were observed on chromosomes 3p and 5q and showed a strong association with 
nuclear grading and a weak correlation with advanced tumor stages112. This method showed 3 
false positive alterations in 20 healthy controls, resulting in 85% specificity112. In this regard, it 
should be noted that the microsatellite alteration analysis was possible only in 9 of the 54 RCC 
patients of Perego’s cohort107. In this study, 55.6% of patients harbored at least one of the 5 
microsatellite markers located on chromosome 3p and these alterations were present also in the 
corresponding primary tumor107. 
Methylation of knows or putative genes occurs frequently in the early stages of RCC. Particularly, 
methylation of Ras association domain family member 1A (RASSF1A) was detected frequently 
in RCC patients. In this regard, a recent analysis showed that RASSF1A is methylated in 22.9% 
of RCC patients115, while a previous study by De Martino et al. demonstrated methylation of 
RASSF1A in 45.9% of patients106. Several other studies reported the methylation of this gene with 
rates ranging from 11% to 62.9% of serum samples of patients with RCC113,114. These differences 
in the RASSF1 gene methylation levels can be explained by the use of different CpG islands for 
analyses and of a bisulfate-based assay in lieu of the methylation-sensitive restriction enzyme 
assay which may be more sensitive. 
Although Ellinger et al. demonstrated a 100% correlation between DNA hypermethylation of the 
RASSF1A promoter and papillary RCC117, De Martino et al. found no association of RASSF1A 
methylation with the papillary RCC analysed106.  
In addition, also the methylation of other genes with a key-role in renal carcinogenesis seem to 
have a diagnostic role. In Hoque’s cohort, 67% of serum samples of RCC patients had methylated 
at least one of the 9 gene promoters113. Besides RASSF1A, methylation was detected frequently 
in TIMP3 and CDH1 genes113. Interestingly, the 6 control patients who displayed serum 
methylation were smokers113. Moreover, VHL methylation was detected more frequently in 
patients with clear cell RCC than in other subtypes, with an ROC value of 0.694106.  
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Hauser et al. found that 85% of the investigated patients has at least one of the 8 genes studied 
methylated and six of the 8 genes were significantly iper-methylated in RCC patients compared 
with healthy individuals115. Despite the ROC analysis showing a high specificity ranging between 
85.2% and 100% for serum cfDNA methylation, sensitivity was low in single-gene analyses115.  
 
 
5. CIRCULATING CELL-FREE METHYLATED DNA AND RENAL CELL 
CARCINOMA 
5.1 DNA methylation and cancer 
DNA methylation is a kind of epigenetic modifications, which adds a methyl group to the 5th 
carbon of cytosine (5-methylcytosine, 5 mC) by DNA methyltransferases (DNMTs) and prefers 
to occur within CpG dinucleotides118.  mC can be oxidized to 5-hydroxymethylcytosine (5hmC), 
5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by ten-eleven translocation (TET) 
proteins. The latter two are excised by thymine DNA glycosylase (TDG) coupled with base 
excision repair (BER), which results in unmodified cytosine119,120. This process is known as active 
DNA demethylation (Figure 1). The dynamic regulation of DNA methylation is a very vital 
process in cell fate determination and development 121. In somatic cells, 5mC is primarily 
restricted to palindromic CpG dinucleotides, and about 60%–80% of CpGs are methylated122. 
Generally, methylated DNA is mainly enriched at promoters and is correlated with inhibition of 
transcription initiation, so DNA methylation has been known as a repressive marker in genome118. 
Aberrant DNA methylation is a noticeable feature of cancer cells 123,124. The cancer genome is 
globally hypomethylated , while hypermethylation of tumor suppressor genes is an early event in 
many tumors, which promotes cancer progression118,125. Growing evidence suggests that 
impairment of active DNA demethylation may contribute to cancer initiation126. Active DNA 
demethylation is TET-mediated. TET1 was initially identified owing to its fusion to mixed-lineage 
leukemia (MLL) in patients with acute myeloid leukemia (AML)127,128.Around the time when 
TET-mediated oxidation of 5 mC was discovered, multiple studies reported TET2-inactivating 
mutations in myeloid disorders128. In addition to TET2 mutations, TET1 and TET3 mutations 
were observed in haematopoietic malignancies129. Mutations of TET proteins are also observed in 
various solid tumors, which causes aberrant active DNA demethylation, as shown by the reduction 
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of 5hmC 126,128. Therefore, global decrease of 5hmC may be broadly used as a diagnostic 
biomarker for cancers119,130. As to another enzyme in demethylation, TDG has also been 
implicated in various cancers, although it may be due to TDG's role in mismatch repair130. 
 
5.2 CfmeDNA as a potential biomarker in cancer. 
Although cfDNA represents a promising biomarker capable of providing diagnostic, prognostic 
and predictive information in many tumor types, clinical routine practice has been slow to adopt 
liquid biopsy, primarily because scientists have struggled in identifying the ideal technical 
approach that would yield robust and reproducible results131.One of the primary challenges of 
cfDNA is that cancer mutation profiles can be highly variable between patients and across tumor 
types. This diversity of mutations represents a significant complication for the development and 
clinical application of cancer tests using cfDNA 132. This may affect sensitivity for many tumor 
types, which is a critical issue in using cfDNA. On the other hand, CpG island methylation is 
characterized as stable133. The stability of this DNA methylation can be leveraged by analyzing 
cfmeDNA in patient plasma133. 
When tumor DNA is shed into the bloodstream, these patterns also become detectable in plasma 
and serum 133. Furthermore, methylation changes are a common feature of different cancer types, 
and occur early in cancer development, typically repressing the expression of tumor suppressor 
genes134. Thus, DNA methylation may offer a more consistent and broadly applicable biomarker 
of tumor DNA in the blood than mutations. These blood-based methylated cfDNA of tumors 
represent the basis of our proposed biomarker development.  
Another obstacles to analyzing traditional ctDNA relate to sensitivity given the limited number of 
recurrent mutations available in order to properly distinguish between tumor and normal 
circulating cfDNA in a cost-effective manner and the technical artefacts as a result of sequencing. 
On the other hand, the use of methylated DNA fragments from cfDNA would overcome these 
issues.  
The advantages of developing cfmeDNA as a biomarker are three-fold: 1) methylation status 
differs between normal and malignant tissues13; 2) methylation status is tissue-specific, which 
permits inference on tissue origin14,15; and 3) the ‘target size’ for methylation is larger than 
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individually identifying a handful of somatically acquired genetic alterations, thereby improving 
dramatically its sensitivity and dynamic range.  
cfmeDNA has the potential to be excellent blood cancer biomarkers. Many proof-of-principle 
studies have indicated that cfmeDNA represent informative and worthwhile blood biomarkers in 
various tumor types and settings135-139 Thus, by varying numbers of differentially methylated 
regions, coverage, and ctDNA abundance, sensitivity is improved , with lower sequencing depth, 
thereby reducing the cost of detection, classification, and monitoring of cancer. In reality this 
practice is labor intensive, and challenging given the low-abundance and fragmented nature of 
plasma cfDNA.140 Indeed most of the previous plasma methylation profiling has been limited to 
locus-specific PCR-based assays.141-143 Alternative approach of cfDNA sequencing have been 
attempted144,145, but were esteemed inefficient146, costly, and with limited information recovery.  
 
5.3 Cell-free methylated DNA immunoprecipitation and high-throughput sequencing 
methodology 
To overcome these technical issues, Daniel De Carvalho developed a novel, optimized 
technology, namely the cfMeDIP-seq (cell-free methylated DNA immunoprecipitation and 
high-throughput sequencing) for genome-wide bisulfite-free plasma DNA methylation 
profiling16. This methodology permits an enrichment for CpG rich, thereby overcoming the 
fragmented nature of plasma cfDNA, and thus enhancing cost-effectiveness. Their first approach 
was the optimization of the gold standard low-input MeDIP-seq protocol, reducing the 100 ng 
input of DNA to only 1-10ng input DNA17, and compared low-input cfMeDIP-seq vs. the original 
standard MeDIP-seq using colorectal cancer samples, which showed robust CpG enrichment and 
inter-replicate correlation. Subsequently, they compared cfMeDIP-seq to ultra-deep unique 
molecular identifiers based, hybrid capture mutation sequencing across a serial dilution of 
colorectal cancer DNA into multiple myeloma. Near-perfect linear associations between the 
observed and expected number of differentially methylated regions were detected. Furthermore, 
they found that cfMEDIP-seq had the ability to enrich ctDNA through biased sequencing of CpG-
rich sequences, which are often hypermethylated in cancer compared to normal tissues147. 
cfMeDIP-seq of plasma cfDNA had the ability to detect tumor-derived DNA methylation events 
in ctDNA, where 45,173 differentially methylated CpGs were found between early-stage 
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pancreatic tumor and normal tissues, as opposed to 14,716 differentially methylated regions 
between cases and controls cfDNA. Based on the discovery that tumor-specific differentially 
methylated regions in the plasma of early-stage pancreatic cancer are detectable with cfMEDIP-
seq, they then sought to assess whether it could also classify various cancer types from healthy 
controls. cfMeDIP-seq was then performed on a discovery cohort of 189 plasma samples obtained 
from seven tumor types, including RCC (early-stage pancreatic cancer, colorectal cancer, breast 
cancer, lung cancer, bladder cancer, acute myeloid leukemia, RCC) and healthy controls. 
Subsequently the performance of cfMeDIP profiles in cancer detection and classification was 
validated in an external ensemble of 199-sample cohort. cfMeDIP-seq was shown to be highly 
accurate in distinguishing tumor and normal tissues. Averaging the class probabilities output by 
E100 for each sample yielded high receiver operating characteristics for distinguishing between 
acute myeloid leukemia vs. other cancers (0.980), pancreatic cancer vs. other (0.918), lung cancer 
vs. others (0.971), normal vs. others (0.969). Taken together, the De Carvalho laboratory 
developed a robust and sensitive, bisulfite-free methodology for immunoprecipitation-based 
profiling of methylation patterns in cfDNA, underlying a highly potent utility of cfDNA 
methylation profiles as the basis for non-invasive and cost-effective early tumor detection for 
cancer interception.16  
 
5.4 Preliminary results 
Our research team at the Dana-Farber Cancer Institute, in collaboration De Carvalho laboratory, 
have produced two pilot data using early stage/metastatic RCC samples by applying the MeDIP-
seq technology, and compared them to 50 RCC samples and 24-non RCC control samples 
obtained from the De Carvalho group. Our findings showed that the metastatic renal cancer 
samples from Boston (in blue) clustered well with the renal samples from Toronto (in green), and 
that both clusters were obviously distinct from the normal clusters (in red, Figure 2A). 
Subsequently we performed the same analysis using six non-metastatic, early-stage RCC samples 
(4 patients had stage I disease, 2 patients had stage II disease). Our findings showed that all the 
renal cancer samples from Boston (in blue) once again clustered well with the ones from Toronto 
(in green), clearly distinct from the non-cancer control samples (in red), evidence that the 




6. RATIONALE AND AIMS 
6.1 Rationale and Hypothesis  
The aforementioned findings are proof-of-concept and preliminary studies that suggest that the 
imaging methods including CT scans and ultrasonography, are currently used for initial diagnosis 
of RCC, which is subsequently confirmed by histologic analysis. These modalities have 
limitations for distinguishing the various types of RCC and are sometimes slow and labor 
intensive. In addition, asymptomatic RCC could be a leading cause of failed early detection of 
kidney cancer. Despite significant progress in the medical treatment of metastatic RCC, RN 
remains the only effective treatment for localized RCC. However, no clinically relevant screening 
assay is currently available to detect asymptomatic RCC and there is, therefore, an urgent need 
for validated markers of RCC. The use of cfDNA, in particular his methylation pattern, could help 
determining early signs of disease and distinguishing benign from malignant renal lesions. 
Because the ‘target size’ for methylation is larger than individually identifying a handful of 
somatically acquired genetic alterations, we hypothesize that cfmeDNA is a more sensitive 
biomarker than targeting plasma DNA variants to diagnose patients with RCC. 
 
6.2 Aim of the study 
Objective: To determine the feasibility of using cfMeDIP-seq technology to detect clear cell RCC 
(ccRCC) cfmeDNA in a plasma samples collected before RN at different pathologic stages – pT1, 
pT2, pT3 and metastatic disease. 
Aim 1: To evaluate if cfMeDIP-seq technology is able to distinguish ccRCC methylation pattern 
from healthy patients pattern.  
Aim 2: To evaluate the sensitivity and specificity of cfmeDNA to detect ccRCC methylation 
pattern in a plasma samples collected before RN at different pathologic stages – pT1, pT2, pT3 





7. MATERIAL AND METHODS 
7.1 Patient selection 
We selected a cohort of 46 patients (test cohort) who had histologically confirmed diagnosis of 
ccRCC between February 2005 and May 2015, and subsequently were followed up at DFCI. 
These cohort was selected based on the availability of a corresponding plasma sample collected 
before the time of surgery and cryopreserved up to processing. Patients demography is 
summarized in table 5. Healthy patients consisted of 10 plasma samples collected between 
November 2017 and December 2018 at DFCI. The training cohorts consisted 24 normal samples 
and 165 plasma samples from cancer patients, of which 20 were ccRCC described in Shen et al 
paper16. 
 
7.2 Ethical remarks 
This research project was governed under a Dana Farber Cancer Institute Institutional Review 
Board (Protocol IRB# 18-515, Role of plasma cell-free methylated DNA immunoprecipitation 
and high-throughput sequencing). 
 
7.3 Sample acquisition 
All patients provided written informed consent, and all samples were obtained upon approval of 
the IRB, according to all relevant ethical regulations. Renal cancer plasma samples were obtained 
from the Dana Farber Cancer Institute – GELB Center Biobank.  
 
7.4 Specimen processing for patient cfDNA 
Plasma samples were collected using EDTA and acid citrate dextrose tubes and were kept frozen 
until use. cfDNA was extracted from 1 ml of plasma using the QIAamp Circulating Nucleic Acid 
Kit (Qiagen) and quantified through Qubit before use.  
 
7.5 cfMeDIP–seq protocol 
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A schematic representation of the cfMeDIP–seq protocol is shown in figure 3. Before cfMeDIP, 
the samples were subjected to library preparation using Kapa HyperPrep Kit (Kapa Biosystems), 
following the manufacturer’s protocol with minor modifications. In brief, after end-repair and A-
tailing, samples were ligated to 0.181 µM of NEBNext adaptor (NEBNext Multiplex Oligos for 
Illumina kit, New England BioLabs) by incubating at 20 °C for 20 min and purified with AMPure 
XP beads (Beckman Coulter). The eluted library was digested using the USER enzyme (New 
England BioLabs) followed by purification with Qiagen MinElute PCR Purification Kit 
(MinElute columns) before MeDIP. 
The prepared libraries were combined with the filler λ DNA (to ensure the total amount of DNA 
(cfDNA + filler) was 100 ng) and subjected to MeDIP with Diagenode MagMeDIP kit 
(C02010021). The filler DNA consists of a mixture of unmethylated and in vitro methylated λ 
amplicons of different CpG densities (Supplementary Table 6), similar in size to adaptor-ligated 
cfDNA libraries. Its addition ensures a constant ratio of antibody to input DNA and helps to 
maintain similar immunoprecipitation efficiency across samples regardless of available cfDNA, 
while minimizing non-specific binding by the antibody and DNA loss due to binding to 
plasticware. For MeDIP, the prepared library/filler DNA mixture was combined with 0.3 ng of 
control methylated and 0.3 ng of the control unmethylated Arabidopsis thaliana DNA provided in 
the kit, and the buffers. The mixture was heated to 95 °C for 10 min, then immediately placed into 
an ice water bath for 10 min. Each sample was partitioned into two 0.2 ml PCR tubes: one for the 
10% input control (7.9 µl) and the other for the sample to be subjected to immunoprecipitation 
(79 µl). The included 5-mC monoclonal antibody 33D3 (C15200081) from the MagMeDIP kit 
was diluted 1:15 before generating the diluted antibody mix and was added to the sample. Washed 
magnetic beads (following the manufacturer’s instructions) were also added before incubation at 
4 °C for 17 h. The samples were purified using the Diagenode iPure Kit v2 (C03010015) and 
eluted in 50 µl of buffer C. The success of the reaction (QC1) was validated by qPCR to detect 
recovery of the spiked-in methylated and unmethylated A. thaliana DNA. The percentage 
recovery of unmethylated spiked-in DNA should be <1% (relative to input control, adjusted for 
input control being 10% of the overall sample) and the percentage specificity of the reaction 
should be >99% (as calculated by (1 – [recovery of spiked-in unmethylated control DNA over 
recovery of spiked-in methylated control DNA]) × 100), before proceeding to the next step. The 
optimal number of cycles to amplify each library was determined by qPCR, after which the 
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samples were amplified using Kapa HiFi Hotstart Mastermix and NEBNext multiplex oligos, 
added to a final concentration of 0.3 µM. The final libraries were amplified as follows: activation 
at 95 °C for 3 min, followed by predetermined cycles of 98 °C for 20 s, 65 °C for 15 s and 72 °C 
for 30 s and a final extension of 72 °C for 1 min. The amplified libraries were purified using Beads 
purification. All the final libraries were submitted for BioAnalyzer analysis before sequencing at 
the Novogene Corporation on an Illumina HiSeq 2500, SBS V4 chemistry, single read 50 bp, 
multiplexed as twelve samples per lane. After sequencing, the sequenced reads were aligned to λ 
and hg19 using Bowtie20 with the default settings. On the basis of virtually no alignment to the λ 
genome, the filler DNA does not interfere with the generation of sequencing data. The generated 
SAM files from hg19 alignment were converted to BAM format, ensuring the removal of duplicate 
reads, and the reads were then sorted and indexed using SAMtools21 before subsequent analysis 
with the R package MEDIPS22. The CpG enrichment score, as a quality control measure for the 
immunoprecipitation reaction, was calculated as part of the MEDIPS package. 
 
7.6 Concentration of cfDNA, calculation and visualization of differentially methylated 
regions from cfDNA of patients with renal cell carcinoma and healthy donors 
The t-test was applied to compare mean values of cfDNA isolated in ccRCC with those isolated 
in healthy patients. A significance level of p=0.05 was used and the  95% Confidence Intervals 
(CIs) were also calculated. All P values were two-tailed. The IBM software Statistical Package 
for Social Sciences (SPSS) version 19.0 for Windows (SPSS Inc. Chicago, Illinois, USA) was 
used for data analysis. DMRs between cfDNA samples from patients with ccRCC and  healthy 
donors were calculated using MEDIPS and DESeq2 R packages22,34. For each sample, we 
computed counts per 300 bp non-overlapping windows, filtered out windows with less than 10 
counts across all samples and fit a negative binomial model to call DMRs at FDR < 0.1 (Wald 
test). z-scores of DMR RPKM values with Euclidean distance and Ward clustering were used for 
visualization. 
7.7 Data reporting 
No statistical methods were used to predetermine sample size. The experiments were not 
randomized. Plasma samples were blinded during the sample preparation and sequencing. Data 




7.8 Bioinformatic simulation of tumour-specific features and probability of detection by 
sequencing depth 
cfMeDIP-seq paired end data were concatenated into single fastqs and were subsequently 
processed using the pipeline described in Shen et al16, to yield RPKMs. These were then 
transformed into log2 (counts per million) estimates and the data were reduced to the 505,000 
300-bp windows of the genome that map to CpG islands, shores, shelves and FANTOM5 
enhancers.  
In order to assess classification performance, we used the ensemble of elastic net models 
previously trained in Shen et al study16. Specifically, we used the classifiers designed to 
distinguish between normal samples and seven types of cancer (bladder cancer, renal cancer, lung 
cancer, breast cancer,pancreatic cancer,colorectal cancer and AML). This model was trained on 
24 normal samples and 165 plasma samples from cancer patients, of which 20 were RCC. 
To build a robust validation cohort to assess performance, we combined the 46 RCC samples 
generated in our lab with 10 normal samples processed in our lab and 62 normal samples 
previously generated for validation in Shen et al study16.  
Class probabilities were generated for our validation cohort, and then ROC curves were 
constructed to estimate performance both across the dataset, and separately for pathological stage 
I, II, III and metastatic samples. We also examined the distributions of class probabilities for both 
the normal samples and the tumours in our dataset. 
 
8. RESULTS 
Concentration of cfDNA in plasma samples of patients with renal cancer and healthy donors. 
Plasma samples in RCC patients were collected from 1 to 109 days before nephrectomy (mean 
26.5±28.8 days). 
The results of the SYBR Green I fluorescence measurements showed that the concentrations of 
cfDNA in patients with RCC range from 1.95 to 260 ng/µL (mean 19.8±39.8 ng/µL ). The range 
of cfDNA concentration in healthy donors was from 3.3 to 17.8 ng/mL (mean 7.9±3.4 ng/µL ). 
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The amount of cfDNA was significantly higher in RCC patients compared to healthy donors 
(p=0.03). 
 
Quality control of cfMeDIP-seq from cfDNA from patients with RCC and healthy controls. 
Specificity of reaction was calculated using methylated and unmethylated spiked-in A. thaliana 
DNA for each sample. As we expected, the recovery of unmethylated spiked in A. thaliana DNA 
was less than 1% and the specificity of each reaction  was more than 99% before the sequencing 
process. 
 
cfMeDIP-seq analysis.  
The elastic net models designed to detect cancer in contrast to normal samples, previously 
published in Shen paper16 showed high performance in discriminating between cancers and 
normal samples across our validation cohort (AUROC = 0.89) (figure 4a). The ROC analysis 
comparing the samples of each pathological stage versus normal samples obtained similar 
AUROC values among the different pathologic stages (figure 4b). Indeed, as represented in the 
bar graphs in figure 5 and 6, all tumors, and only a fraction of normal samples, had class 
probabilities of close to 1 for being called malignant.  
While applying a naïve probability threshold of 0.5 yields poor sensitivity at high specificity 
(Specificity = 1, sensitivity = 0.31) across the dataset, the high ROC values suggest that 
remarkably higher sensitivity should be possible with an optimised threshold, albeit with 
concomitant drops in specificity.  
 
9. Discussion 
The use of liquid biopsies for cancer detection and management is rapidly gaining prominence. In 
particular, the analysis of ctDNA has numerous potential clinical applications. However, certain 
settings, such as cancer screening and the detection of minimal residual disease after treatment, 
require a degree of analytical sensitivity that is often beyond current technical limits of mutation-
based ctDNA detection methods. Current methods for the detection of ctDNA involve sequencing 
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somatic mutations using cfDNA, but the sensitivity of these methods may be low among patients 
with early-stage cancer given the limited number of recurrent mutations.  
By contrast, large-scale epigenetic alterations, which are tissue- and cancer-type specific, are not 
similarly constrained and therefore potentially have greater ability to detect and classify cancers 
in patients with early-stage disease. Recent studies demonstrate that cfmeDNA may be useful 
biomarkers and there are many prospective studies of the clinical utility of cfmeDNA. However, 
a lot of challenges for cfDNA methylation analysis still remain, and the major challenge is that 
current approaches are essentially adapted to examining methylation in genomic DNA. Almost 
all of the cfDNA methylation analysis methods depend on bisulfite sequencing, which can cause 
a degree of DNA degradation. WGBS provides whole methylation information in cfDNA, but this  
CfMeDIP-seq is a sensitive immunoprecipitation-based protocol to analyze the methylome of 
small quantities of cfDNA with the ability to detect large-scale DNA methylation changes that are 
enriched for tumor-specific patterns. The methodology also demonstrated robust performance in 
cancer detection and classification across an extensive collection of plasma samples from several 
tumor types in a cost-effective manner, reducing technical artefacts introduced during sequencing. 
In our study, for the first time we tested the cfMeDIP-seq methodology in an independent set of 
48 ccRCC plasma samples collected before RN at different pathologic stages – pT1, pT2, pT3 and 
metastatic disease. We showed that the methylation pattern of cfDNA is able to distinguish healthy 
patients from ccRCC patients. Then we clearly demonstrate the presence of ccRCC methylation 
pattern in the cfDNA of patients before RN at different stages, suggesting that cfDNA could be 
able to detect early stage of disease and might detect minimal residual disease after RN.  
In particular, the elastic net models designed to detect cancer in contrast to normal samples, showed 
high performance in discriminating between cancers and normal samples across the validation 
cohort (AUROC = 0.89). The ROC analysis comparing the samples of each pathological stage 
versus normal samples obtained similar AUROC values among the different pathologic stages, 






This is a new way to approach the study cfDNA. Most of the known methods have struggled to 
analyze ctDNA because of the sensitivity given to the limited number of recurrent mutations 
available to properly distinguish between tumor and normal cfDNA in a cost-effective manner 
and the technical artefacts as a result of sequencing. 
A major limitation of the previous analysis is that we don’t have a small number of healthy patients  
in our validation dataset. This prohibits an accurate estimation of both the sensitivity and 
specificity which need to be assessed to evaluate the clinical utility of our approach.  
A strong point of our study is that the cfMeDIP-seq approach has a large methylation ‘target size’, 
because it is not focused on identify individually somatically acquired genetic alterations, but the 
whole methylation pattern,  improving dramatically the sensitivity and dynamic range. Although 
the amount of cfDNA was significantly higher in RCC patients compared to healthy donors 
(p=0.03), cannot be considered a reliable diagnostic tool. In fact, the level of cfDNA is not 
sufficiently robust to distinguish between cancer and non-cancer, because it is influenced by 
concomitant diseases and other clinical factors, and therefore it. 
In addition, our protocol requires 1 to 10 ng input DNA. The amount of DNA is very compare to 
the gold-standard MeDIP–seq (100 ng), reduced representation bisulfite sequencing (RRBS) 
(1,000 ng) and WGBS (2,000 ng). 
Because the methylation status differs between normal and malignant tissues and it is tissue-
specific, the cfMeDIP–seq technology could be used to detect various cancer. In fact, our research 
team at the Dana-Farber Cancer Institute, in collaboration with the De Carvalho laboratory has 
effectively tested the reproducibility of cfMeDIP–seq in a cohort of patients with muscle-invasive 
bladder cancer (MIBC). We selected 12 pts who underwent RC for MIBC - 6patients who had 
recurrent disease within 2-3yrs after radical cystectomy RC (C1) and 6 pts who did not (C2). 119 
healthy pts without bladder cancer were controls. Also in this case, cfDNA was isolated from 1ml 
of plasma samples collected after RC and before recurrence (C1) or during the follow-up (C2) and  
was analyzed by the cfMeDIP-seq using 10ng input cfDNA. The amount of cfDNA isolated from 
1ul of plasma was very similar to what we found in RCC cohorts, 13.1ng (6.4-19.7) in C1 and 
17.1ng (13.6-21.2) in C2. 
In this case, we identified approximately 137,000 peaks which were present at least in one sample 
and the supervised classification identified 61 DMR (FDR<0.050), predominantly located in 
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intergenic region, which distinguished C1 from C2. The randomized sample tests proved the 
discriminatory power of the identified set. Moreover, the supervised analysis comparing the status 
of the identified DMRs relative to healthy controls showed 28 regions were differentially 
methylated (logFC > +/- 1, FDR < 0.05), clearly demonstrating that cfmeDNA can be readily 
harvested from MIBC patients to detect cancer-specific methylation patterns and predict 
recurrence of MIBC post-RC.  
 
10. Conclusion 
Although cfMeDIP–seq method awaits further validation in completely independent datasets, our 
findings in RCC patients and the preliminary results in MIBC patients underscore the potential 
utility of cfDNA methylation profiles as a basis for non-invasive, cost-effective, sensitive and 



















Table 1. American Joint Committee on Cancer (AJCC) TNM Staging System for Kidney Cancer 8th ed., 2017). 



















Table 2. Summary of the studies evaluating cfDNA in RCC. 
 
 
AML angiomyolipoma; MN metanephric nephroma; NR, not reported; OCT oncocytoma; RCC, renal cell carcinoma; TCC, transitional cell 









Patients (n) Control (n) Source 
Material 
Isolated Method Detection 
method 
Goessl et al.116, 
1998 
Prospective Diagnostic  
 
 40 RCC 10 healthy 
individuals 
Plasma, 1ml Qiamp Blood  Kit (Qiagen, Hilden, Germany). Fluorescent PCR 
Eisenberger et 
al.111, 1999  
Prospective Diagnostic  25 RCC 
   1 AML 
   1 MN 
   3 OCT 
8 individualsa with 
nephrolithiasis 
8  healthy individuals 
Serum, NR Digestion with proteinase K (Boehringer Mannheim 
GmbH, Mannheim, Germany) in the presence of 
sodium dodecyl sulfate at 48 °C overnight, followed 





Prospective Diagnosic   53 RCC 
    1 renal B cell 
lymphoma 
    6 TCC 
20 healthy 
individuals 
Serum, 2-4ml Qiamp Midi-Kit (Qiagen, Hilden, Germany) Fluorescent PCR 
Hoque et al.113, 
2005 





Serum, nr Digestion with 50 μg/ml proteinase K (Boehringer, 
Mannheim, Germany) in the presence of 1% SDS at 
48°C overnight, followed by phenol/chloroform 
extraction and ethanol precipitation. 
Fluorescence-based 
RT-PCR (Taqman) 




  48 RCC 
    1 TCC 





QIAamp DNA Mini kit (Qiagen, Italy)  qRT-PCR (-
globin) 
Hauser et al.110, 
2010 
 
Prospective  Diagnostic, 
Prognostic 
  35 RCC 54 healthy 
individuals 
Serum, 1ml ChargeSwitch gDNA Kit (Invitrogen, 
Paisley,Scotland) 
qRT-PCR (actin-) 
Feng et al.148, 
2010 
Prospective Diagnostic  
 
  78 RCC 42 healthy 
individuals 
Serum, 400l QIAamp DNA Blood Mini Kit (Qiagen, 
Courtaboeuf,France)  
qRT-PCR (actin-) 
De Martino et 
al.106, 2011 
Prospective Diagnostic  
Prognostic  
157 RCC 43 benign renal 
tumors 




Hauser et al.110, 
2013 
 
Prospective Diagnostic  
 
 35 RCC 54 healthy 
individuals 





Prospective Diagnostic  27 RCC 15 healthy  
individuals 
Plasma, 2ml Proba Na kit (DNA-Technology, Russia) qRT-PCR (actin-) 
35 
 
Table 3. Diagnostic information of microsatellite alterations (loss of heterozygosity and/or microsatellite instability) in RCC. 
 
 
AML angiomyolipoma; MN metanephric nephroma; NR, not reported; OCT oncocytoma; RCC, renal cell carcinoma; TCC, transitional cell 
carcinoma; MA, microsatellite alterations (loss of heterozygosity and/or microsatellite instability) 









Study Microsatellite markers Patients (n) Control (n) Sensitivity Specificity 
Goessl et al.116, 1998 D3S1307(3p), D3SI560(3p), D3SI289(3p), 
D3SI300(3p) 
 40 RCC 10 healthy individuals 63%  (at least one MA) 
35%   (more than one MA) 
100% 
Eisemberger et al.111, 
1999  
D1S251 (1pq), HTPO(2p), D3S1317(3p), 
D3S587(3p), D3S1560(3p), D3S1289(3p), D3S1286 
(3p), D3S1038(3p) , D4S243(4pq), FGA(4)(4q), 
CSF(5q), ACTBP2(5p), D8S348(8q), D8S307(8p), 
D9S747(9p), D9S242(9p), IFNa(9p), D9S162(9p), 
D11S488(11q), THO(11p), vWA(12p), 
D13S802(13q), MJD(14q), D17S695(17p), 
D17S654(17p), D18S51(18q), MBP(18q), 
D21S1245(21q). 
 25 RCC 
   1 AML 
   1 MN 
   3 OCT 
8 individualsa with   
   nephrolithiasis 
8  healthy individuals 
60%  (at least one MA) 100% 
Knobloch et al.112, 2002 D3S1560(3p), D3S2450(3p), D3S3666(3p), 
D3S2408(3p), D3S1259(3p), D5S1720(5p), 
D5S1480(5p), D5S476(5p), D5S818(5p), 
D7S1796(7p), D7S1807(7p), D8S261(8p), 
D8S560(8p), D9S925(9p), D13S153(13p), 
D17S799(17p), D17S1306 (17p), D17S783(17p), 
D17S1298(17p), D17S807(17p) 
53 RCC 
  1 renal B cell lymphoma 
  6 TCC  
 
20 healthy individuals 
 
 
74% (using 9 MA)   
87% (using 20 MA) 
85% 
Perego et al.107, 2008 D3S1566(3p), D3S1285(3p), D3S1300(3p), 
D3S1289(3p), D3S1597(3p)  
 
48 RCC 
  1 TCC 
  5 OCT 
 
41 healthy individuals 55.6% (at least one MA)* NR 
36 
 
Table 4. Diagnostic information of cfDNA methylation in RCC and controls. 
 
 
APC, adenomatosis-poliposis-coli gene; ARF, ARF tumor suppressor protein gene; CDH1, cadherin-1 gene; FHIT, fragile histidine triad gene; GSTP1, gluthation-
a-transferase-protein 1 gene; ITGA9, integrin subunit alpha 9 gene;  LRRC3B , leucine rich repeat containing 3B gene; MGMT, O-6-methylguanine-DNA 
methyltransferase gene; NR, not reported; p16, cyclin-dependent kinase inhibitor 2A;  PTGS2, prostaglandin-endoperoxidase synthase; RAR-82, retinoic acid 
receptor beta; RCC, renal cell carcinoma; RAR-B  retinoid-acid-receptor-beta gene; RASSF1A Ras association domain family member 1A; TIMP3, tissue inhibitor 
of metalloproteinase-gene, VHL, von Hippel-Lindau. 
 
 
Study Markers  Number of methylation 
positive/number of total 
RCC patients (%) 
 Number of methylation 
positive/number of total 
controls case (%) 
Sensitivity (%) Specificity (%) Cutoff 
value 
AUC Source Detection 
method 
Hoque et al.113, 
2005 
APC  1/18 (5.5) 1/30 (3.3) 5.5 96.7 4.5 NR Serum,NR Fluorescence-based 
real-time PCR 
(Taqman) 
ARF  1/18  (5.5) 1/30 (3.3) 5.5 96.7 0 NR 
CDH1  6/18 (33.3) 2/30 (6.6) 33.3 93.4 0.3 NR 
GSTP1  1/18 (5.5) 0/30 (0) 5.5 100 0 NR 
MGMT  0/18 (0) 1/30 (3.3) 0 96.7 0 NR 
p16  4/18 (22.2) 0/30 (0) 22.2 100 0 NR 
RAR-82  1/18 (5.5) 0/30 (0) 5.5 100 0.1 NR 
RASSF1A  2/18 (11.1) 1/30 (3.3) 11.1 96.7 0.1 NR 
TIMP3  3/18 (16.6) 0/30 (0) 17 100 1 NR 
De Martino et al.106, 
2011 
RASSF1A  72/157 (45.9) 3/43 (7) 45.9 93 0 0.694 Serum, 1ml Restriction 
endonuclease q-PCR PTGS2  60/157 (38.2) 15/43 (34.9) 38.2 65.1 0 0.517 
P16  73/157 (46.5) 19/43 (44.2) 46.5 55.8 0 0.512 
VHL  79/157 (50.3) 4/43 (8.3) 50.3 90.7 0 0.705 
Hauser et al.115, 
2013 
APC 19/35(54.3) 5/54 (9.3) 54.3 90.7 0.37 0.72 Serum, 1ml Methylation-sensitive 
restriction enzymes GSTP1 6/35 (17.1) 1/54 (1.9) 17.1 98.1 0.75 0.57 
p14(ARF) 5/35 (14.3) 0/54 (0) 14.3 100 0.26 0.57 
P16 9/35 (25.7) 9/54 (16.7) 25.7 83.3 0 NR 
PTGS2 8/35 (22.9) 2/54 (3.7) 22.9 96.3 0.47 0.59 
RAR-B 14/35 (40) 8/54 (14.8) 40.0 85.2 0.19 0.61 
RASSF1A 8/35 (22.9) 1/54 (1.9) 22.9 98.2 0.09 0.60 
TIMP3 20/35 (57.1) 21/54 (38.9) 57.1 61.1 0 NR 
Skrypkina et al.114, 
2016 
APC 14/27 (51.9) 1 /15(6.7) 51.9 93.3 0 NR Plasma, 2ml Methylation-specific 
polymerase chain 
reaction (MS-PCR) 
FHIT 15/27 (55.6) 0/15 (0) 55.6 100 0 NR 
ITGA9 0 /27(0) 0/15 (0) 0 100 0 NR 
LRRC3B 20/27 (74.1) 5/15 (33.3) 74.1 66.7 0 NR 
RASSF1  17/27 (63.0 ) 1/15 (6.7) 62.9 93.3 0 NR 




Table 5. Main characteristics of study patients (N = 46)   
 
 




























































Figure. 1. The dynamic regulation of DNA methylation and aberrant DNA methylation in cancer. DNA 
methyltransferases (DNMTs) convert unmodified cytosine to 5-methylcytosine (5 mC). Ten-eleven 
translocation (TET) enzymes can oxidize 5 mC to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC). Thymine DNA glycosylase (TDG)/base excision repair (BER) pathway excises 




















Figure 2. Differentially methylated regions (DMRs) were identified by comparing: the two Renal_B 
(Boston/blue dots) samples to a set of 24 normal samples (red) and the 20 Renal_T (Toronto/green) to normal 
(A) and the six Renal_B (Boston/blue dots) samples to a set of 24 normal samples (red) and the 20 Renal_T 
(Toronto/green) to normal (B). Using a dimensional reduction technique, t-distributed stochastic neighbor 
embedding (t-SNE), the samples can be distinguished and co-cluster with the Toronto samples  
 


































































Figure 4. ROC curves – y axis = sensitivity, x axis = specificity. Curves were constructed to distinguish 
between normal and RCC samples in a cohort of 118 samples. AUROC values are printed (a). Further 






















Figured 5. Barplots – y axis = probability of the sample being classified as malignant based on an 
ensemble of classifiers trained on 20 RCC and 24 normals in Shen paper16. The barplots for the 
tumour sample are coloured by stage, and the barplots of the normal samples are coloured by the 













































Figure 6. Heatmap. Heatmap shows all windows that were originally selected during the training 
of an ensemble classifier to discriminate between normal and cancer samples in a 189 sample 
discovery cohort consisting of eight classes, previously described and published in Shen paper16. 
Rows represent features, columns represent samples. Annotation ribbons highlight 
cancer/normal status, the probability allocated by the classifier, and the source of the data, 
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